Results 81 to 90 of about 15,674 (165)

Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.
Rana R. McKay, Wanling Xie, Archana Ajmera, Arlene Araneta, Edmund Folefac, Arif Hussain, Christos E. Kyriakopoulos, Adam Olson, Mamta Parikh, Rahul Parikh, Biren Saraiya, Geoffrey I. Shapiro   +11 more
wiley   +1 more source

PVT1 lincRNA signals an androgen‐dependent transcriptional activation program of oncogenes in prostate cancer cells

International Journal of Cancer, Volume 159, Issue 1, Page 144-158, 1 July 2026.
What's New? Unraveling the networks that regulate androgen receptor (AR) function is critical to better understanding prostate cancer development and progression. Of particular interest in this regard is the long non‐coding RNA PVT1, which regulates gene expression in cancer and is upregulated in prostate tumors.
Maria Gabriela Berzoti‐Coelho, Fabio Nunes de Mello, Ana Carolina Tahira, Gabriel Nakanishi Fortes, Agatha Fischer‐Carvalho, Pedro Jardim Poli, Murilo Sena Amaral, Sergio Verjovski‐Almeida   +7 more
wiley   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer

The Prostate, Volume 86, Issue 10, Page 1103-1114, July 2026.
ABSTRACT Background The management of intermediate‐risk early prostate cancer (PCa) is challenging due to the difficulty in distinguishing indolent from aggressive tumors. This study explores the association between genomic alterations and the tumor and its microenvironment (TME) and implications for disease progression. Methods We performed multi‐omic
William Lautert‐Dutra, Camila M. Melo, Luiz P. Chaves, Francisco C. Souza, Vida Talebian, Cheryl Crozier, Mary Anne Quintayo, Linda Liao, Dan Dion, Fabiano P. Saggioro, Felipe S. Avante, Rodolfo B. dos Reis, Jeremy A. Squire, Jane Bayani   +13 more
wiley   +1 more source

Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis

The Prostate, Volume 86, Issue 10, Page 1170-1173, July 2026.
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros, Clara Rodrigo, Laura Ferrer‐Mileo, Laia Fernández‐Mañas, Joel Mases, Nely Diaz, Antoni Vilaseca, Mariana Altamirano, Roser Gibanel, Maria José Ribal, Natalia Jimenez, Oscar Reig, Mariona Figols, Miguel Ángel Climent, Albert Font, Begoña Mellado   +15 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, Volume 20, Issue 6, Page 1626-1642, June 2026.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Impact of the Nadir Androgen Receptor Signaling Inhibitor-Derived Integrative Response Model in Real-World Patients With Metastatic Castration-Sensitive Prostate Cancer. [PDF]

Prostate
ABSTRACT Background Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC).
Yukihiro K, Sekino Y, Goto K, Saito K, Fujiyama K, Kagiyama Y, Kurimura Y, Fukuoka K, Naito M, Miyamoto S, Kobatake K, Kitano H, Goriki A, Hieda K, Hinata N.   +14 more
europepmc   +2 more sources

Cervical Skip Metastases and Extensive Central Venous Thrombosis as the Initial Presentation of High‐Grade Prostate Adenocarcinoma With Discordant PI‐RADS 3 Findings: A Case Report and Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Prostate cancer can initially present with cervical lymph node “skip” metastases and extensive central venous thrombosis, without pelvic or bone involvement. A PI‐RADS 3 lesion on mpMRI does not exclude high‐grade (Gleason 5 + 5 = 10) disease. Unexplained thrombosis in elderly men warrants prostate cancer investigation.
Yuchun Luo, Benhui Lai, Juncheng Huang
wiley   +1 more source

Genetic ancestry–concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration‐resistant prostate cancer

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background The authors observed differences in response between Black and White patients with metastatic castration‐resistant prostate cancer (mCRPC) who were treated prospectively with androgen receptor pathway inhibition (ARPI) in the Abi Race and PANTHER studies.
Sean A. Piwarski, Lauren E. Howard, Morgan A. Paul, Nick Bachelder, Bonnie LaCroix, Angela Clayton, Donna Allen, Julie Kephart, Andrew J. Armstrong, Steven R. Patierno, Daniel J. George, Terry Hyslop, Jennifer A. Freedman   +12 more
wiley   +1 more source

Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Prostate cancer (PC) arising in patients with low testosterone is often more aggressive and less responsive to androgen deprivation therapy (ADT). This study evaluated whether baseline testosterone group (low vs. normal) modifies the mortality benefit of adding docetaxel to radiation therapy (RT) and ADT in nonmetastatic high‐risk ...
Johnathan Zeng, Ming‐Hui Chen, Jing Wu, Wanling Xie, Praful Ravi, Paul Nguyen, Howard Sandler, Anthony V. D’Amico   +7 more
wiley   +1 more source